Investigating Combinational Approaches to Elevate GLP-1 Therapies: Role of 2nd Generation ASK1 Inhibitor SRT-015 Treatment for MASH Fibrosis
Time: 2:20 pm
day: Conf Day 1 Track 2 PM
Details:
- SRT-015 is an oral compound with direct pleotropic effects on the liver including fibrotic, inflammatory and apoptosis inhibition for possible use in all MASH fibrosis stages
- Combination therapy with GLP-1s and other metabolic agents
- In a Phase 1 clinical trial, SRT-015 demonstrated pharmacokinetics that enables daily dosing with a favorable safety profile
